Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor

Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide's commercial launch in essential tremor, with pipeline optionality limited. I maintain a cautious Hold rating, as PRAX trades above my fair value estimate of $223.73 versus a current share price of $265. Key risks include real-world persistence, payer step edits, and competition from cheap off-label generics, which could materially limit ulixacaltamide's addressable market and duration.

Seeking Alpha • 19 hours ago

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET.

GlobeNewsWire • Jun 4, 2026

The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive

Praxis Precision Medicines unexpectedly halted enrollment in a late-stage study of its seizure drug. Praxis stock tumbled.

Investors Business Daily • Jun 2, 2026

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures.

Benzinga • Jun 2, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Jun 2, 2026

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the ​main goal of a mid- to late-stage ‌study, prompting it to pause enrollment in another ongoing study while it reassesses the program.

Reuters • Jun 1, 2026

Praxis Precision Medicines Provides Vormatrigine Program Update

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10% Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (FOS). “While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile,” said Marcio Souza, President and Chief Executive Officer of Praxis.

GlobeNewsWire • Jun 1, 2026

Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Seeking Alpha • May 13, 2026

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 9, 2026

Praxis Precision Medicines Q1 Earnings Call Highlights

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 results and pipeline updates on the company's earnings call.

MarketBeat • May 8, 2026